drugset / Trial / NCT05892068
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
Phase 2
Active not recruiting
9 enrolled
Memorial Sloan Kettering Cancer Center
Pfizer · collabSeagen Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study to see how the brain absorbs, distributes, and gets rid of tucatinib in people who have HER2+ cancers (breast cancer, NSCLC, CRC, or GEC) that have spread to the brain, and to learn more about how cancer cells develop resistance to treatment. The researchers will do research tests to look for genetic differences between HER2+ breast cancer that has spread to the brain and progressed during treatment with tucatinib and cancers that are being treated with tucatinib for the first time.
Timeline
- Start
- 2023-05-09
- Primary completion
- 2028-05-09
- Completion
- 2028-05-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tucatinib | Small molecule | 300 mg | Oral |